Mitigating aberrant Cdk5 activation alleviates mitochondrial defects and motor neuron disease symptoms in spinal muscular atrophy

Spinal muscular atrophy (SMA), the top genetic cause of infant mortality, is characterized by motor neuron degeneration. Mechanisms underlying SMA pathogenesis remain largely unknown. Here, we report that the activity of cyclin-dependent kinase 5 (Cdk5) and the conversion of its activating subunit p...

Full description

Saved in:
Bibliographic Details
Published inProceedings of the National Academy of Sciences - PNAS Vol. 120; no. 47; p. e2300308120
Main Authors Miller, Nimrod, Xu, Zhaofa, Quinlan, Katharina A, Ji, Amy, McGivern, Jered V, Feng, Zhihua, Shi, Han, Ko, Chien-Ping, Tsai, Li-Huei, Heckman, Charles J, Ebert, Allison D, Ma, Yongchao C
Format Journal Article
LanguageEnglish
Published United States National Academy of Sciences 21.11.2023
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Spinal muscular atrophy (SMA), the top genetic cause of infant mortality, is characterized by motor neuron degeneration. Mechanisms underlying SMA pathogenesis remain largely unknown. Here, we report that the activity of cyclin-dependent kinase 5 (Cdk5) and the conversion of its activating subunit p35 to the more potent activator p25 are significantly up-regulated in mouse models and human induced pluripotent stem cell (iPSC) models of SMA. The increase of Cdk5 activity occurs before the onset of SMA phenotypes, suggesting that it may be an initiator of the disease. Importantly, aberrant Cdk5 activation causes mitochondrial defects and motor neuron degeneration, as the genetic knockout of in an SMA mouse model rescues mitochondrial transport and fragmentation defects, and alleviates SMA phenotypes including motor neuron hyperexcitability, loss of excitatory synapses, neuromuscular junction denervation, and motor neuron degeneration. Inhibition of the Cdk5 signaling pathway reduces the degeneration of motor neurons derived from SMA mice and human SMA iPSCs. Altogether, our studies reveal a critical role for the aberrant activation of Cdk5 in SMA pathogenesis and suggest a potential target for therapeutic intervention.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
1N.M. and Z.X. contributed equally to this work.
Edited by Michael Greenberg, Harvard Medical School, Boston, MA; received January 6, 2023; accepted July 31, 2023
ISSN:0027-8424
1091-6490
DOI:10.1073/pnas.2300308120